Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Terguride in stable Parkinson's disease

E Martignoni1, C Pacchetti, B Aufdembrinke

  • 1Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.

Functional Neurology
|May 1, 1995
PubMed
Summary

Terguride (TER) did not significantly differ from placebo in maintaining stable Parkinson's disease (PD) symptoms during levodopa (LD) reduction. While TER showed some dopamine-like effects, its antiparkinsonian efficacy was minimal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deontological Guilt Differentially Affects Moral Behaviour in Participants With and Without Obsessive-Compulsive Disorder (OCD).

Clinical psychology & psychotherapy·2026
Same author

Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives.

Endocrine-related cancer·2025
Same author

Development and Characterization of a 13-Plex Binding Assay to Detect <i>Shigella</i> Antibodies in Human Samples.

Open forum infectious diseases·2024
Same author

Combined evaluation of prolactin-induced peptide (PIP) and extracellular signal-regulated kinase (ERK) as new sperm biomarkers of FSH treatment efficacy in normogonadotropic idiopathic infertile men.

Journal of endocrinological investigation·2023
Same author

Correction to: Gender differences in microRNA expression in levodopa‑naive PD patients.

Journal of neurology·2023
Same author

Gender differences in microRNA expression in levodopa-naive PD patients.

Journal of neurology·2023

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) management often involves levodopa (LD), but long-term efficacy can wane.
  • Exploring add-on therapies to reduce LD dosage and mitigate side effects is crucial.

Purpose of the Study:

  • To evaluate Terguride (TER) as an add-on therapy to reduce levodopa (LD) dosage in stable Parkinson's disease (PD) patients.
  • To assess the efficacy of TER in maintaining patient stability during LD reduction.

Main Methods:

  • A randomized, placebo-controlled trial involving 41 stable PD patients.
  • TER (2 mg/day) or placebo was administered as add-on therapy for 4 weeks, followed by a 25% reduction in LD dosage.
  • Patient stability was assessed using the Columbia University Rating Scale (CURS) score, with an increase of no more than 20% defining stability.

Related Experiment Videos

Main Results:

  • Most patients remained stable despite the 25% LD reduction, with no significant differences between TER and placebo groups.
  • The CURS score showed a decrease over time exclusively within the TER group.
  • TER demonstrated dopaminergic (DA-ergic) properties but exhibited minimal antiparkinsonian efficacy.

Conclusions:

  • Terguride (TER) is a drug with dopaminergic (DA-ergic) properties.
  • TER shows minimal efficacy as an add-on treatment for reducing levodopa (LD) dosage in stable Parkinson's disease (PD) patients.
  • Further research may be needed to explore alternative therapeutic strategies for PD.